IMDXInsight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests,…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript FDA review nears completion as reimbursement rates support commercial launch. | ||
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing Insight Molecular Diagnostics discussed the potential use of donor-derived cell-free DNA testing in heart transplant surveillance during a virtual session featuring transplant cardiologist Dr. Max Liebo of Loyola University. Chief Executive Officer Josh Riggs said the company’s GraftAssureDx test i | ||
 Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary Moby summary of Insight Molecular Diagnostics Inc.'s Q2 2026 earnings call | ||
Oncocyte Q2 Earnings Call Highlights Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial launch and managing spending ahead of expected revenue growth. During the company’s second-quarter call | ||
IInsider Monkey | ||